Search Results - therapeutics+%3e+hematology

18 Results

Sort By:

Alleviating GvHD Using Engineered INKT Cells (UCLA Case No. 2023-019)

SUMMARY: Researchers in UCLA’s Department of Microbiology, Immunology & Molecular Genetics have developed an off-the-shelf cell therapy method for reduction of Graft vs Host Disease (GvHD) following hematopoietic stem cell transplantation. This approach uses engineered third-party iNKT’s to ameliorate severity of GvHD without negatively...

Published: 2/15/2024 | Inventor(s): Lili Yang

Keywords(s): Hematology, Stem-Cell Therapy, T Cell, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Hematology

2018-680: Single-Chain Bispecific Chimeric Antigen Receptor Targeting BCMA And CS1 For The Treatment Of Multiple Myeloma

SUMMARY UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a single-chain bispecific chimeric antigen receptor targeting BCMA and CS1 for treating multiple myeloma. BACKGROUND Multiple myeloma (MM) is a cancer of the plasma cells that accounts for over 30,000 new diagnoses each year, according to the American...

Published: 1/16/2024 | Inventor(s): Yvonne Chen, Eugenia Zah

Keywords(s): Hematology, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Therapeutics, Therapeutics > Hematology, Therapeutics > Immunology And Immunotherapy

2021-189: NOVEL AND ROBUST COMBINATORY THERAPY FOR AORTIC ANEURYSMS

SUMMARY: Researchers from UCLA’s Department of Anesthesiology have developed an oral combinatory therapy that holds enormous implications in healthcare for the complete attenuation of aneurysm formation. BACKGROUND: Aortic aneurysms are abnormal protrusions in the major blood vessels from the heart to the rest of the body. These protrusions...

Published: 7/19/2023 | Inventor(s): Hua Linda Cai

Keywords(s):

Category(s): Therapeutics > Cardiovascular, Therapeutics > Hematology

2021-043 NOVEL IGE ANTIBODIES FOR THE THERAPY OF CANCER

Researchers at UCLA’s David Geffen School of Medicine have designed three novel antibodies of the IgE class targeting antigens CD138, CD38, and transferrin receptor 1 (TfR1/CD71): cancer antigens present in various hematopoietic and/or solid tumors. There are several advantages of IgE class antibodies compared to the commonly used IgG class in...

Published: 2/15/2024 | Inventor(s): Manuel Penichet, Pierre Candelaria, Miguel Nava, Tracy Wells

Keywords(s): Cancer, Immunoglobulin G

Category(s): Platforms > Drug Delivery > Peptide Base, Therapeutics > Hematology

2020-416 Automated Screening of Sickle Cells Using a Smartphone-Based Microscope and Deep Learning

SUMMARYUCLA researchers in the Department of Electrical & Computer Engineering have developed an automated method for detecting sickle cell disease (SCD) using a smartphone-based microscope and deep learning.BACKGROUNDSickle cell disease (SCD) is a preventable disease that affects millions of people world-wide. Current screening methods involve...

Published: 7/19/2023 | Inventor(s): Aydogan Ozcan, Yair Rivenson, Kevin deHaan, Hatice Ceylan Koydemir

Keywords(s):

Category(s): Software & Algorithms > Image Processing, Software & Algorithms > Digital Health, Life Science Research Tools > Microscopy And Imaging, Life Science Research Tools > Cell Counting And Imaging, Platforms > Diagnostic Platform Technologies, Therapeutics > Hematology

2015-795 Novel Optimized Drug Combinations for Drug-Resistant and Drug-Sensitive Multiple Myeloma Developed Using a Systematic Phenotypic Personalized Medicine Drug Development Platform

SUMMARYUCLA Researchers in the Departments of Bioengineering and School of Medicine and Co-inventors from The National University of Singapore have developed a drug development platform for optimized drug combination and dosage for drug-resistant multiple myeloma patients.BACKGROUNDMultiple myeloma is a plasma cell malignancy that leads to significant...

Published: 7/19/2023 | Inventor(s): Dean Ho, Chih-Ming Ho

Keywords(s):

Category(s): Life Science Research Tools, Therapeutics > Hematology

2019-870 GENE EDITING OF MONOGENIC DISORDERS IN HUMAN HEMATOPOIETIC STEM CELLS (XHIM)

Researchers at the UCLA Department of Microbiology, Immunology & Molecular Genetics have developed novel methods to achieve efficient, precise gene integration and effective expression of cDNA cassettes to express normal versions of genes in hematopoietic stem cells. BACKGROUND:Hematopoietic stem cells (HSCs)—stem cells that give rise to...

Published: 7/19/2023 | Inventor(s): Donald Kohn

Keywords(s): Gene Editing Systems, Gene Therapy, Genetic Disease, Hematology, Immunotherapy, iPS/stem cells, Therapeutics & Vaccines, Viral Delivery Systems

Category(s): Therapeutics > Gene Therapy And Editing, Therapeutics > Hematology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Stem Cells And Regenerative Medicine > Ips Stem Cells

2013-741 Bioengineered Thymic Aggregates for Implantation

Bioengineered Thymic Aggregates For ImplantationSUMMARYResearchers led by Gay Crooks from the Department of Pathology and Laboratory Medicine at UCLA have bioengineered a thymus implant to treat immune diseases.BACKGROUNDThe thymus plays an important role in the immune cells by producing specialized white blood cells called T cells. Thymus implantation...

Published: 7/19/2023 | Inventor(s): Gay Crooks, Amelie Montel Hagen, Brile Chung

Keywords(s): Autoimmune, Drug Delivery, Hematology, Inflammatory Diseases, Other Polymers, Therapeutics & Vaccines

Category(s): Platforms > Drug Delivery, Therapeutics > Autoimmune, Therapeutics > Hematology, Platforms > Drug Delivery > Other Polymers, Therapeutics > Immunology And Immunotherapy

2019-728 NOVEL LIPID LOWERING, ANTI-ATHEROSCLEROSIS AND ANTI-OBESITY EFFECTS OF NETRIN-1

UCLA researchers in the Department of Anesthesiology have developed a novel and extremely robust lipid lowering, anti-atherosclerotic, and anti-obesity treatment with Netrin-1.BACKGROUND:Hyperlipidemia, an elevation of different forms of lipids in the bloodstream, is the most important risk factor for coronary heart disease, while causing many other...

Published: 9/5/2023 | Inventor(s): Hua Linda Cai

Keywords(s): Cardiovascular, Hematology, Therapeutics & Vaccines

Category(s): Therapeutics > Cardiovascular, Therapeutics > Hematology

2006-064 DESIGNING AN IMPROVED KUNITZ DOMAIN 1 OF TFPI-2 MOLECULE FOR THERAPEUTICS

Improved Highly Potent Specific Human Kunitz Inhibitor of Fibrinolytic Enzyme PlasminTech ID: 30531 / UC Case 2019-981-0SUMMARYUCLA researchers in the School of Medicine have developed mutant polypeptides of the tissue factor pathway inhibitor-2 (TFPI-2) Kunitz domain 1 (KD1), which can serve as potent inhibitors of fibrinolysis.BACKGROUNDFibrinolysis,...

Published: 7/19/2023 | Inventor(s):

Keywords(s): Hematology, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Hematology

1 2